GlassScriptPhysician profile
Troy R Ogden
NPI 1023246386
$7,377.00
in general payments reported to CMS, 2019-2025
23 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $262 · 2021: $503 · 2022: $1,279 · 2023: $1,388 · 2024: $1,749 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105 · Consulting Fee: $242 · Entertainment: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,105.05 |
| Consulting Fee | $241.68 |
| Entertainment | $154.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,992.57 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,084.09 | 2022-2025 | Infuse, Infuse Multifocal, Alden Scleral Zenlens |
| Coopervision INC. | $1,029.90 | 2019-2025 | Myday Contact Lens, Paragon Crt, Onefit Contact Lens |
| Alcon Vision LLC | $923.46 | 2019-2025 | Precision7, Total30, Acrysof, Iq Restor |
| Biotissue Holdings INC. | $391.17 | 2024-2025 | |
| Sight Sciences, INC. | $286.84 | 2023 | Tearcare System |
| Lkc Technologies, INC. | $172.06 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $159.24 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $159.12 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.63 | 2019-2020 | |
| Optos, INC. | $154.26 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abb Con-Cise Optical Group LLC | $129.14 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $116.42 | 2021-2025 | |
| Allergan, INC. | $101.63 | 2022 | |
| Shire North American Group INC | $101.08 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $82.03 | 2020 | |
| Dompe US, INC. | $76.96 | 2024 | Oxervate |
| Abbvie INC. | $71.34 | 2024 | |
| Mallinckrodt Hospital Products INC. | $58.42 | 2021 | |
| Maculogix, INC. | $55.01 | 2021 | |
| Glaxosmithkline, LLC. | $38.04 | 2022 | |
| Astellas Pharma US INC | $20.97 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $16.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.